Allogeneic hematopoieteic stem cell transplantation (HSCT) is the only curative treatment for
myelofibrosis (MF), but it is still associated with significant risks and complications. One of …

Myelofibrosis (MF) is a chronic progressive hematologic malignancy with a median overall
survival (OS) of approximately 6 years. Allogeneic hematopoietic stem cell transplantation …

Primary myelofibrosis (PMF) or myelofibrosis secondary to polycythemia vera (PV-MF) or
essential thrombocythemia (ET-MF) can be cured only by means of allogeneic …

Methods: This is an observational retrospective study of 15 consecutive patients with MF
who underwent allogeneic HSCT at a tertiary care center in Northern India between June …

Primary myelofibrosis (PM) is a rare chronic myeloproliferative disorder with a variable
prognosis [1]. The etiology is not completely understood yet, but it is possible to demonstrate …

Prognostic and therapeutic considerations remain a challenging aspect in the appropriate
care of patients with myelofibrosis. Critical to these considerations are the use and …

Introduction: Allogeneic stem cell transplantation (SCT) is a curative option recommended
for patients with Dynamic International Prognostic Scoring System (DIPSS) intermediate-2 …

Primary myelofibrosis (PMF) is a BCR-ABL1 negative myeloproliferative neoplasm
characterized by clonal proliferation of myeloid cells. This leads to reactive bone marrow …

BACKGROUND. Previous prognostic studies in primary myelofibrosis have focused on risk
factors for overall survival and have resulted in the establishment of several prognostic …

Aim: Dynamic assessment of trends over time in patient-and transplant-specific
characteristics and outcomes for patients undergoing 1 st allogeneic haematopoietic cell …